JPMorgan Chase & Co. lowered shares of Shire (LON:SHP) to a neutral rating in a research report released on Tuesday. JPMorgan Chase & Co. currently has GBX 3,600 ($49.74) price target on the biopharmaceutical company’s stock, down from their prior price target of GBX 5,000 ($69.08).
A number of other analysts have also recently weighed in on SHP. Liberum Capital decreased their price objective on Shire from GBX 4,400 ($60.79) to GBX 4,200 ($58.03) and set a hold rating for the company in a research report on Tuesday, October 24th. Berenberg Bank decreased their price objective on Shire from GBX 6,000 ($82.90) to GBX 5,900 ($81.51) and set a buy rating for the company in a research report on Tuesday, October 24th. Shore Capital reaffirmed a buy rating on shares of Shire in a research report on Thursday, October 26th. Deutsche Bank reissued a buy rating and set a GBX 5,700 ($78.75) target price on shares of Shire in a research note on Thursday, October 26th. Finally, Citigroup reissued a buy rating and set a GBX 5,500 ($75.99) target price on shares of Shire in a research note on Monday, October 30th. Five research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of Buy and a consensus price target of GBX 5,073.53 ($70.10).
Shares of Shire (LON SHP) opened at GBX 3,072.50 ($42.45) on Tuesday. Shire has a 1 year low of GBX 3,033 ($41.90) and a 1 year high of GBX 5,067 ($70.01). The firm has a market capitalization of $27,980.00 and a P/E ratio of 589.73.
In other news, insider Dominic Blakemore acquired 165 shares of the company’s stock in a transaction that occurred on Tuesday, December 19th. The stock was purchased at an average cost of GBX 3,790 ($52.36) per share, with a total value of £6,253.50 ($8,639.82).
TRADEMARK VIOLATION WARNING: “JPMorgan Chase & Co. Downgrades Shire (SHP) to Neutral” was first posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this article can be accessed at https://www.chaffeybreeze.com/2018/02/21/jpmorgan-chase-co-downgrades-shire-shp-to-neutral.html.
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.